查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1956465

哺乳動物細胞生物製藥CDMO服務市場報告：趨勢、預測與競爭分析（至2031年）

Mammalian Biologics CDMO Service Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 178 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

由於中小企業和大型企業市場的機遇，全球哺乳動物細胞生物製藥CDMO服務市場預計將保持強勁成長，並預計從2025年到2031年將以10.1%的複合年成長率成長。主要市場促進因素包括對生物療法的需求不斷成長、對生產外包解決方案的需求不斷成長以及對開發創新生物藥物的日益重視。

  • Lucintel 預測，在預測期內，細胞和基因療法將在所有療法類別中呈現最高的成長率。
  • 在應用類別中，大型企業市場預計將呈現更高的成長率。
  • 從區域來看，預計亞太地區在預測期內將達到最高的成長率。

哺乳動物細胞生物製藥CDMO服務市場的新興趨勢

哺乳動物細胞生物製藥CDMO服務市場正經歷快速成長，這主要得益於生物技術的進步、個人化醫療需求的不斷成長以及對高效生產解決方案的需求。隨著製藥和生技公司尋求加速藥物研發並降低成本，市場也不斷演進，湧現出創新技術和策略聯盟。這些發展正在改變生技藥品的生產、測試和上市方式，為產業相關人員帶來新的機會和挑戰。對於希望保持競爭力並有效利用新市場動態的公司而言，了解這些新興趨勢至關重要。

  • 一次性技術的應用：這一趨勢表明，生物製藥生產中一次性生物反應器和設備的使用正在增加。一次性系統具有柔軟性、污染風險低、資本投入少等優點，並能快速放大生產規模與製程變更。推動其應用的因素是對經濟高效、擴充性且高效的生產流程的需求，尤其是在個人化醫療和小批量生產領域。這種轉變提高了營運彈性，縮短了周轉時間，使生物製藥生產能夠更好地適應市場需求。
  • 進階分析與人工智慧的融合：人工智慧 (AI) 和先進數據分析技術的應用正在變革生物製藥生產的流程最佳化、品管和預測性維護。 AI 驅動的工具能夠實現即時監控、異常檢測和流程調整，從而提高產量並確保產品品質的穩定性。這種融合降低了生產成本，縮短了研發週期，並加強了合規性。隨著數據驅動決策成為常態，企業能夠在生物製藥研發方面實現更高的效率和創新。
  • 契約製造擴張：我們看到，合約研發生產機構 (CDMO) 大幅提升了其哺乳動物生物製藥的生產能力。這一擴張是由市場對生物製藥，特別是單株抗體和基因療法藥物日益成長的需求所驅動的。 CDMO 正在投資建造最先進的設施、先進的生物反應器和聘請熟練的專業人員，以滿足客戶的需求。這一趨勢使生技公司能夠將生產外包，縮短產品上市時間，並專注於研發，從而創造一個更具協作性和靈活性的產業環境。
  • 關注永續性和綠色製造：環境問題和監管壓力正迫使企業在生物製藥生產中採用永續的做法。這包括減少能源消耗、廢棄物產生和用水量，以及採用環保材料和製程。綠色製造不僅能最大限度地減少對環境的影響，也符合企業社會責任目標和監管標準。這一趨勢正在推動產業轉型，促進永續生物加工技術的創新，並建立更負責任的供應鏈。
  • 個人化醫療和細胞療法的興起：個人化醫療和細胞療法市場正經歷著爆發式成長，這需要專門的生產過程。合約研發生產機構（CDMO）正在開發靈活且擴充性的平台，以高效生產個人化療法。這一趨勢的驅動力來自基因組學、再生醫學和免疫療法的進步，這些領域需要高度客製化和快速的生產週期。向個人化生物製劑的轉變正在改變市場格局，強調敏捷性、創新性和對監管的快速反應，以滿足每位患者的獨特需求。

總而言之，這些新興趨勢正在透過提高生產效率、增加創新和注重永續性來重塑哺乳動物細胞生物製藥 CDMO 服務市場，從而支持更短的開發週期、降低成本和個人化醫療的發展，最終形成一個更具活力和響應能力的行業格局。

哺乳動物細胞生物製藥CDMO服務市場的最新趨勢

由於生技藥品需求不斷成長、生物技術研究取得進展以及對專業化生產服務的需求，哺乳動物細胞生物製藥CDMO服務市場正經歷快速成長。隨著製藥和生物技術公司尋求高效、擴充性且合規的生技藥品生產解決方案，市場正透過創新技術和策略聯盟不斷發展。這些發展正在重塑市場格局，從而提高產品品質、加快產品上市速度並擴大全球覆蓋範圍。以下關鍵發展突顯了這個充滿活力的市場的當前方向和未來潛力。

  • 擴大產能和基礎設施：為滿足日益成長的哺乳動物源生物製藥需求，領先的合約研發生產機構（CDMO）正投資建設新設施併升級現有設施。這些擴建將提高生產能力、縮短前置作業時間並增強服務，從而加速向全球患者提供生物製藥療法。
  • 採用先進的生物製程技術：連續製程、一次性系統和自動化整合正在變革生物製劑的生產。這些技術提高了效率、降低了成本並改善了產品的一致性，從而為企業在市場競爭中帶來優勢。
  • 策略聯盟與夥伴關係：各公司正與生物技術公司、學術機構和技術提供者結盟，以獲得創新平台並擴展其服務組合，從而縮短開發時間並促進生物製藥製造領域的創新。
  • 注重合規性和品質標準：加強對全球法規結構的遵守，確保產品的安全性和有效性。合約研發生產機構（CDMO）實施嚴格的品管體系，以建立客戶信任並促進順利的核准流程。
  • 對客製化和專業服務的需求不斷成長：市場對客製化生物製藥生產解決方案的需求不斷成長，包括細胞株開發、製程最佳化和填充包裝服務，這反映了對個人化療法和複雜生物製藥的需求。

總之，這些發展正透過擴大產能、提陞技術整合、促進策略合作、確保合規性以及滿足個人化醫療需求，對哺乳動物細胞生物製藥CDMO服務市場產生重大影響。這些措施共同推動市場成長，提升服務質量，並實現生技藥品更快、更有效率的研發和生產。

目錄

第1章執行摘要

第2章 市場概覽

  • 背景和分類
  • 供應鏈

第3章：市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

4. 全球哺乳動物生技藥品CDMO服務市場（按類型分類）

  • 吸引力分析：按類型
  • 細胞和基因治療
  • 抗體
  • 疫苗
  • 其他

5. 全球哺乳動物細胞生物製藥CDMO服務市場（依應用領域分類）

  • 吸引力分析：依目的
  • 小型企業
  • 主要企業

第6章 區域分析

7. 北美哺乳動物細胞生物製藥CDMO服務市場

  • 北美哺乳動物細胞生物製藥CDMO服務市場（按類型分類）
  • 北美哺乳動物細胞生物製藥CDMO服務市場（按應用領域分類）
  • 美國哺乳動物細胞生物製藥CDMO服務市場
  • 加拿大哺乳動物細胞生物製藥CDMO服務市場
  • 墨西哥哺乳動物細胞生物製藥CDMO服務市場

8. 歐洲哺乳動物細胞生物製藥CDMO服務市場

  • 歐洲哺乳動物細胞生物製藥CDMO服務市場（按類型分類）
  • 歐洲哺乳動物細胞生物製藥CDMO服務市場依應用領域分類
  • 德國哺乳動物細胞生物製藥CDMO服務市場
  • 法國哺乳動物細胞生物製藥CDMO服務市場
  • 義大利哺乳動物細胞生物製藥CDMO服務市場
  • 西班牙哺乳動物細胞生物製藥CDMO服務市場
  • 英國哺乳動物細胞生物製藥CDMO服務市場

9. 亞太地區哺乳動物細胞生物製藥CDMO服務市場

  • 亞太地區哺乳動物細胞生物製藥CDMO服務市場（按類型分類）
  • 亞太地區哺乳動物細胞生物製藥CDMO服務市場（依應用分類）
  • 中國哺乳動物細胞生物製藥CDMO服務市場
  • 印度哺乳動物細胞生物製藥CDMO服務市場
  • 日本哺乳動物細胞生物製藥CDMO服務市場
  • 韓國哺乳動物細胞生物製藥CDMO服務市場
  • 印尼哺乳動物細胞生物製藥CDMO服務市場

10. 其餘哺乳動物生技藥品CDMO服務市場

  • 世界其他地區哺乳動物細胞生物製藥CDMO服務市場（按類型分類）
  • 世界其他地區哺乳動物細胞生物製藥CDMO服務市場（按應用領域分類）
  • 中東哺乳動物細胞生物製藥CDMO服務市場
  • 南美洲哺乳動物細胞生物製藥CDMO服務市場
  • 非洲哺乳動物源性生技藥品CDMO服務市場

第11章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析
  • 市佔率分析

第12章：機會與策略分析

  • 價值鏈分析
  • 成長機會分析
  • 全球哺乳動物細胞生物製藥CDMO服務市場新興趨勢
  • 戰略分析

第13章 價值鏈主要企業的公司概況

  • Competitive Analysis Overview
  • Lonza
  • Catalent
  • Samsung Biologics
  • FUJIFILM Diosynth Biotechnologies
  • Boehringer Ingelheim
  • WuXi AppTech
  • Recipharm
  • Thermo Fisher Scientific
  • AGC Biologics
  • Rentschler Biopharma

第14章附錄

簡介目錄

The future of the global mammalian biologics CDMO service market looks promising with opportunities in the SMB and large company markets. The global mammalian biologics CDMO service market is expected to grow with a CAGR of 10.1% from 2025 to 2031. The major drivers for this market are the increasing demand for biologic therapies, the rising need for outsourced manufacturing solutions, and the growing focus on innovative biologic drug development.

  • Lucintel forecasts that, within the type category, cell & gene therapy is expected to witness the highest growth over the forecast period.
  • Within the application category, large company is expected to witness higher growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Mammalian Biologics CDMO Service Market

The mammalian biologics CDMO service market is experiencing rapid growth driven by advancements in biotechnology, increasing demand for personalized medicine, and the need for efficient manufacturing solutions. As pharmaceutical and biotech companies seek to accelerate drug development and reduce costs, the market is evolving with innovative technologies and strategic collaborations. These developments are transforming how biologics are produced, tested, and brought to market, creating new opportunities and challenges for industry stakeholders. Understanding these emerging trends is crucial for companies aiming to stay competitive and leverage new market dynamics effectively.

  • Adoption of Single-Use Technologies: This trend involves the increasing use of disposable bioreactors and equipment in biologics manufacturing. Single-use systems offer flexibility, reduced contamination risk, and lower capital investment, enabling faster scale-up and process changes. Their adoption is driven by the need for cost-effective, scalable, and efficient manufacturing processes, especially for personalized medicines and small-batch productions. This shift enhances operational agility and reduces turnaround times, making biologics production more adaptable to market demands.
  • Integration of Advanced Analytics and AI: The use of artificial intelligence and advanced data analytics is transforming process optimization, quality control, and predictive maintenance in biologics manufacturing. AI-driven tools enable real-time monitoring, anomaly detection, and process adjustments, leading to higher yields and consistent product quality. This integration reduces manufacturing costs, shortens development timelines, and enhances regulatory compliance. As data-driven decision-making becomes standard, companies can achieve greater efficiency and innovation in biologics development.
  • Expansion of Contract Manufacturing Capabilities: There is a significant increase in the number of CDMOs expanding their mammalian biologics manufacturing capacities. This expansion is driven by rising demand for biologics, especially monoclonal antibodies and gene therapies. CDMOs are investing in state-of-the-art facilities, advanced bioreactors, and a skilled workforce to meet client needs. This trend allows biotech firms to outsource manufacturing, reduce time-to-market, and focus on R&D, fostering a more collaborative and flexible industry environment.
  • Focus on Sustainability and Green Manufacturing: Environmental concerns and regulatory pressures are prompting companies to adopt sustainable practices in biologics production. This includes reducing energy consumption, waste generation, and water usage, as well as implementing eco-friendly materials and processes. Green manufacturing not only minimizes environmental impact but also aligns with corporate social responsibility goals and regulatory standards. This trend is reshaping the industry by encouraging innovation in sustainable bioprocessing technologies and fostering a more responsible supply chain.
  • Rise of Personalized and Cell-Based Therapies: The market is witnessing a surge in personalized medicine and cell-based therapies, requiring specialized manufacturing processes. CDMOs are developing flexible, scalable platforms to produce individualized treatments efficiently. This trend is driven by advancements in genomics, regenerative medicine, and immunotherapy, demanding high customization and rapid production cycles. The shift towards personalized biologics is transforming the market landscape, emphasizing agility, innovation, and regulatory adaptation to meet the unique needs of each patient.

In summary, these emerging trends are reshaping the mammalian biologics CDMO service market by enhancing manufacturing efficiency, fostering innovation, and emphasizing sustainability. They are enabling faster development cycles, reducing costs, and supporting the growth of personalized medicine, ultimately leading to a more dynamic and responsive industry landscape.

Recent Developments in the Mammalian Biologics CDMO Service Market

The mammalian biologics CDMO service market is experiencing rapid growth driven by increasing demand for biologics, advancements in biotechnological research, and the need for specialized manufacturing services. As pharmaceutical and biotech companies seek efficient, scalable, and compliant solutions for biologic production, the market is evolving with innovative technologies and strategic collaborations. These developments are shaping the landscape, enhancing product quality, reducing time-to-market, and expanding global reach. The following key developments highlight the current trajectory and future potential of this dynamic market.

  • Expansion of Capacity and Infrastructure: Major CDMOs are investing in new facilities and upgrading existing ones to meet rising demand for mammalian biologics. This expansion improves manufacturing capacity, reduces lead times, and enhances service offerings, enabling faster delivery of biologic therapies to patients worldwide.
  • Adoption of Advanced Bioprocessing Technologies: Integration of continuous processing, single-use systems, and automation is transforming biologics manufacturing. These technologies increase efficiency, reduce costs, and improve product consistency, giving companies a competitive edge in the market.
  • Strategic Collaborations and Partnerships: Companies are forming alliances with biotech firms, academic institutions, and technology providers to access innovative platforms and expand their service portfolios. Such collaborations accelerate development timelines and foster innovation in biologic production.
  • Focus on Regulatory Compliance and Quality Standards: Enhanced emphasis on compliance with global regulatory frameworks ensures product safety and efficacy. CDMOs are adopting rigorous quality management systems, which build trust with clients and facilitate smoother approval processes.
  • Growing Demand for Custom and Specialized Services: The market is witnessing increased demand for tailored biologic manufacturing solutions, including cell line development, process optimization, and fill-finish services. This trend reflects the need for personalized therapies and complex biologic products.

In summary, these developments are significantly impacting the mammalian biologics CDMO service market by increasing capacity, improving technological integration, fostering strategic collaborations, ensuring regulatory compliance, and catering to personalized medicine needs. Collectively, they are driving market growth, enhancing service quality, and enabling faster, more efficient biologic drug development and manufacturing.

Strategic Growth Opportunities in the Mammalian Biologics CDMO Service Market

The mammalian biologics CDMO service market is experiencing rapid expansion driven by increasing demand for biologics across various industries such as pharmaceuticals, biotechnology, and research institutions. Advances in biotechnological research, rising prevalence of chronic diseases, and the need for specialized manufacturing services are fueling this growth. Companies are focusing on innovative solutions to meet stringent regulatory standards and reduce time-to-market for new biologics. As the market evolves, key applications are presenting significant growth opportunities that can shape the future landscape of biologics development and manufacturing.

  • Enhancing Productivity and Stability: The development of high-yield, stable cell lines is crucial for efficient biologics production, leading to faster development cycles and reduced costs, thereby attracting more clients seeking reliable manufacturing solutions.
  • Improving Efficiency and Scalability: Focus on refining bioprocesses to ensure higher yields, lower production costs, and scalable solutions, which are vital for meeting increasing global demand for biologics.
  • Accelerating Drug Approval Processes: Providing high-quality, compliant clinical trial materials helps pharmaceutical companies expedite clinical phases, reducing time-to-market and increasing market competitiveness.
  • Ensuring Regulatory Compliance and Large-scale Production: Scaling up production while maintaining quality standards is essential for market supply, enabling companies to meet global demand and expand their market share.
  • Ensuring Product Safety and Efficacy: Advanced testing and validation services ensure biologics meet regulatory standards, fostering trust and facilitating smoother approval processes across markets.

In summary, these growth opportunities are significantly impacting the mammalian biologics CDMO service market by driving innovation, improving efficiency, and ensuring regulatory compliance. This, in turn, accelerates the development and commercialization of biologics, fostering market expansion and increased competitiveness.

Mammalian Biologics CDMO Service Market Driver and Challenges

The mammalian biologics CDMO service market is influenced by a complex interplay of technological advancements, economic factors, and regulatory frameworks. As the biopharmaceutical industry continues to evolve, the demand for specialized contract development and manufacturing services for mammalian biologics grows. Innovations in cell line development, process optimization, and scalable manufacturing technologies are key drivers. Simultaneously, economic considerations such as rising R&D investments and the need for cost-effective production methods shape market dynamics. Regulatory compliance and quality standards also significantly impact market growth, ensuring safety and efficacy. Navigating these multifaceted factors is crucial for stakeholders aiming to capitalize on emerging opportunities while addressing inherent challenges.

The factors responsible for driving the mammalian biologics CDMO service market include:

  • Technological Innovation: The rapid development of advanced bioprocessing technologies, such as high-yield cell line development and continuous manufacturing, enhances production efficiency and product quality. These innovations enable CDMOs to meet the increasing demand for complex biologics, reduce time-to-market, and improve scalability. As biopharmaceutical companies seek more reliable and cost-effective manufacturing solutions, technological progress becomes a pivotal driver, fostering market expansion and competitiveness.
  • Rising Biopharmaceutical R&D Investment: The global increase in R&D expenditure by pharmaceutical and biotech companies fuels demand for specialized CDMO services. As companies focus on developing novel biologics, they require expert manufacturing partners to handle complex processes. This investment trend supports the growth of the mammalian biologics CDMO market by expanding capacity, encouraging innovation, and enabling faster development cycles, ultimately accelerating the availability of new therapies.
  • Growing Prevalence of Chronic Diseases: The rising incidence of chronic conditions such as cancer, autoimmune disorders, and infectious diseases drives demand for biologic therapies. These therapies often require sophisticated manufacturing processes provided by mammalian cell-based systems. The increasing need for personalized and targeted treatments further amplifies the demand for high-quality biologics, positioning CDMOs as essential partners in delivering these advanced medicines.
  • Regulatory Support and Quality Standards: Stringent regulatory frameworks and quality assurance protocols ensure the safety and efficacy of biologics. While compliance can be challenging, it also creates opportunities for specialized CDMOs to offer validated, compliant manufacturing solutions. The evolving regulatory landscape encourages innovation in quality management and process validation, fostering trust and facilitating market entry for new biologics.
  • Strategic Collaborations and Partnerships: Collaborations between biopharmaceutical companies and CDMOs enable resource sharing, risk mitigation, and access to advanced technologies. These strategic alliances accelerate development timelines and expand manufacturing capacity. As the market becomes more competitive, such partnerships are vital for innovation, cost reduction, and market penetration, thereby driving overall industry growth.

The challenges facing this mammalian biologics CDMO service market include:

  • High Capital and Operational Costs: Establishing and maintaining mammalian cell culture facilities require significant investment in infrastructure, equipment, and skilled personnel. These costs can be prohibitive for smaller firms and may limit market entry. Additionally, operational expenses related to raw materials, quality control, and regulatory compliance add to financial burdens, potentially impacting profitability and scalability.
  • Complex Regulatory Environment: Navigating diverse and evolving regulatory requirements across different regions poses a significant challenge. Ensuring compliance with Good Manufacturing Practices (GMP), validation protocols, and safety standards demands substantial resources and expertise. Regulatory delays or non-compliance can hinder product approval, increase costs, and affect market competitiveness.
  • Technological Uncertainties and Risks: Despite advancements, bioprocessing technologies are inherently complex and susceptible to variability. Risks such as process failures, contamination, and batch inconsistencies can lead to delays and increased costs. Keeping pace with rapid technological changes also requires continuous investment in innovation and staff training, which can strain resources and impact operational stability.

In summary, the mammalian biologics CDMO service market is shaped by significant technological innovations, increasing R&D investments, and rising disease prevalence, all of which foster growth. However, high costs, regulatory complexities, and technological risks pose substantial hurdles. The interplay of these drivers and challenges determines the market's trajectory, requiring stakeholders to strategically navigate evolving landscapes. Successful adaptation to these factors will be essential for sustained growth and competitive advantage in this dynamic industry.

List of Mammalian Biologics CDMO Service Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies mammalian biologics CDMO service companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the mammalian biologics CDMO service companies profiled in this report include-

  • Lonza
  • Catalent
  • Samsung Biologics
  • FUJIFILM Diosynth Biotechnologies
  • Boehringer Ingelheim
  • WuXi AppTech
  • Recipharm
  • Thermo Fisher Scientific
  • AGC Biologics
  • Rentschler Biopharma

Mammalian Biologics CDMO Service Market by Segment

The study includes a forecast for the global mammalian biologics CDMO service market by type, application, and region.

Mammalian Biologics CDMO Service Market by Type [Value from 2019 to 2031]:

  • Cell & Gene Therapies
  • Antibodies
  • Vaccines
  • Others

Mammalian Biologics CDMO Service Market by Application [Value from 2019 to 2031]:

  • SMBs
  • Large Companies

Mammalian Biologics CDMO Service Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Mammalian Biologics CDMO Service Market

The mammalian biologics CDMO service market is experiencing rapid growth driven by increasing demand for biologics, advancements in biotechnologies, and expanding pharmaceutical pipelines worldwide. As companies seek specialized manufacturing solutions, regions are innovating to meet regulatory standards and improve production efficiency. The United States, China, Germany, India, and Japan are key players, each contributing unique developments that shape the global landscape. These countries are investing heavily in research, infrastructure, and strategic collaborations to enhance their capabilities and competitiveness in this evolving market.

  • United States: The US market is witnessing significant investments in advanced bioprocessing technologies and automation. Leading firms are expanding their facilities to accommodate complex biologics, with a focus on personalized medicine and cell therapy manufacturing. Regulatory agencies are streamlining approval processes, fostering innovation, and faster market entry. The US also sees increased collaborations between biotech startups and CDMOs to accelerate product development.
  • China: China is rapidly emerging as a major hub for biologics manufacturing, with government initiatives supporting biotech innovation. The country is expanding its CDMO infrastructure, focusing on cost-effective production and quality improvements. Chinese firms are investing in advanced bioreactor systems and quality control measures to meet international standards. Strategic partnerships with Western companies are also on the rise, boosting technological transfer and expertise.
  • Germany: Germany remains a leader in biopharmaceutical manufacturing within Europe, emphasizing high-quality standards and regulatory compliance. The country is advancing in the development of single-use bioreactors and continuous manufacturing processes. German CDMOs are increasingly adopting digital solutions for process optimization and data management. The focus is on sustainable practices and reducing environmental impact in biologics production.
  • India: India's biologics CDMO sector is expanding rapidly, driven by a large pool of skilled scientists and cost advantages. The country is investing in state-of-the-art manufacturing facilities and quality assurance systems. Indian companies are focusing on biosimilars and generic biologics, catering to both domestic and international markets. The government's supportive policies are encouraging foreign direct investment and technology transfer.
  • Japan: Japan is strengthening its biologics manufacturing capabilities through innovation in cell culture technologies and bioprocessing. The country is emphasizing quality and safety, aligning with stringent regulatory standards. Japanese CDMOs are adopting automation and AI-driven analytics to improve efficiency. There is also a focus on developing therapies for aging-related diseases, with collaborations between academia and industry fostering new advancements.

Features of the Global Mammalian Biologics CDMO Service Market

  • Market Size Estimates: Mammalian biologics CDMO service market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Mammalian biologics CDMO service market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Mammalian biologics CDMO service market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the mammalian biologics CDMO service market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the mammalian biologics CDMO service market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the mammalian biologics CDMO service market by type (cell & gene therapies, antibodies, vaccines, and others), application (SMBs and large companies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Mammalian Biologics CDMO Service Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Cell & Gene Therapies : Trends and Forecast (2019-2031)
  • 4.4 Antibodies : Trends and Forecast (2019-2031)
  • 4.5 Vaccines : Trends and Forecast (2019-2031)
  • 4.6 Others : Trends and Forecast (2019-2031)

5. Global Mammalian Biologics CDMO Service Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 SMBs : Trends and Forecast (2019-2031)
  • 5.4 Large Companies : Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Mammalian Biologics CDMO Service Market by Region

7. North American Mammalian Biologics CDMO Service Market

  • 7.1 Overview
  • 7.2 North American Mammalian Biologics CDMO Service Market by Type
  • 7.3 North American Mammalian Biologics CDMO Service Market by Application
  • 7.4 The United States Mammalian Biologics CDMO Service Market
  • 7.5 Canadian Mammalian Biologics CDMO Service Market
  • 7.6 Mexican Mammalian Biologics CDMO Service Market

8. European Mammalian Biologics CDMO Service Market

  • 8.1 Overview
  • 8.2 European Mammalian Biologics CDMO Service Market by Type
  • 8.3 European Mammalian Biologics CDMO Service Market by Application
  • 8.4 German Mammalian Biologics CDMO Service Market
  • 8.5 French Mammalian Biologics CDMO Service Market
  • 8.6 Italian Mammalian Biologics CDMO Service Market
  • 8.7 Spanish Mammalian Biologics CDMO Service Market
  • 8.8 The United Kingdom Mammalian Biologics CDMO Service Market

9. APAC Mammalian Biologics CDMO Service Market

  • 9.1 Overview
  • 9.2 APAC Mammalian Biologics CDMO Service Market by Type
  • 9.3 APAC Mammalian Biologics CDMO Service Market by Application
  • 9.4 Chinese Mammalian Biologics CDMO Service Market
  • 9.5 Indian Mammalian Biologics CDMO Service Market
  • 9.6 Japanese Mammalian Biologics CDMO Service Market
  • 9.7 South Korean Mammalian Biologics CDMO Service Market
  • 9.8 Indonesian Mammalian Biologics CDMO Service Market

10. ROW Mammalian Biologics CDMO Service Market

  • 10.1 Overview
  • 10.2 ROW Mammalian Biologics CDMO Service Market by Type
  • 10.3 ROW Mammalian Biologics CDMO Service Market by Application
  • 10.4 Middle Eastern Mammalian Biologics CDMO Service Market
  • 10.5 South American Mammalian Biologics CDMO Service Market
  • 10.6 African Mammalian Biologics CDMO Service Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunity by Type
    • 12.2.2 Growth Opportunity by Application
  • 12.3 Emerging Trends in the Global Mammalian Biologics CDMO Service Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis Overview
  • 13.2 Lonza
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Catalent
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Samsung Biologics
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 FUJIFILM Diosynth Biotechnologies
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Boehringer Ingelheim
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 WuXi AppTech
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Recipharm
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 Thermo Fisher Scientific
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 AGC Biologics
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 Rentschler Biopharma
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us